The FDA said early evidence suggested blood plasma can decrease mortality and improve the health of patients.
The United States Food and Drug Administration on Sunday approved the “emergency use” of blood plasma from recovered coronavirus patients as a treatment against the infection, reported AFP. The FDA said early evidence suggested blood plasma can decrease mortality and improve the health of patients when administered in the first three days of their hospitalisation. The US has so far registered over 1.77 lakh coronavirus deaths – the highest in the world. “This product may be effective in treating COVID-19 and… the known and potential benefits of the product outweigh the known and potential risks of the product,” the agency said in a statement. So far,70,000 patients have been treated using blood plasma, said the FDA. “It appeared that the product is safe and we’re comfortable with that and we continue to see no concerning safety signals,” said Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, according to Reuters.
